Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active AntiRetroviral Therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS).

Trial Profile

Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active AntiRetroviral Therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Selumetinib (Primary) ; Antiretrovirals
  • Indications HIV infections; Kaposi's sarcoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms SCART
  • Most Recent Events

    • 08 Jan 2018 Planned End Date changed from 1 feb 2016 to 1 Jun 2018.
    • 08 Jan 2018 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top